2020
DOI: 10.1038/s41598-020-59417-1
|View full text |Cite
|
Sign up to set email alerts
|

Prevalence and risk factors of having antibodies to class I and II human leukocyte antigens in older haploidentical allograft candidates

Abstract: The effect of donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) has been recognized as a factor in graft failure (GF) in patients who underwent umbilical cord blood transplantation (UBT), matched unrelated donor transplantation (MUDT), or haploidentical stem cell transplantation (haplo-SCT). Presently, we know little about the prevalence of and risk factors for having anti-HLA antibodies among older transplant candidates. Therefore, we analyzed 273 older patients with hematologic disease who … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
12
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(14 citation statements)
references
References 36 publications
(35 reference statements)
2
12
0
Order By: Relevance
“…Regardless of the MFI cut-off value of anti-HLA antibodies as ≥500, ≥1000, ≥1500, ≥2000, ≥5000, or ≥ 10,000, transfusion and pregnancy were the two most important risk factors for anti-HLA antibodies, as previously described. 2,13,14,18,[21][22][23] In our study, the reason for the different effects of RBC transfusion and platelet transfusion on anti-HLA antibody production may be that RBCs express low levels of HLA class I molecules (100-2000 per cell), whereas platelets are rich in HLA molecules. 34,35 This supports our finding that platelet transfusion, but not RBC transfusion, is a more important risk factor for the production of anti-HLA antibodies.…”
Section: Discussionmentioning
confidence: 69%
See 3 more Smart Citations
“…Regardless of the MFI cut-off value of anti-HLA antibodies as ≥500, ≥1000, ≥1500, ≥2000, ≥5000, or ≥ 10,000, transfusion and pregnancy were the two most important risk factors for anti-HLA antibodies, as previously described. 2,13,14,18,[21][22][23] In our study, the reason for the different effects of RBC transfusion and platelet transfusion on anti-HLA antibody production may be that RBCs express low levels of HLA class I molecules (100-2000 per cell), whereas platelets are rich in HLA molecules. 34,35 This supports our finding that platelet transfusion, but not RBC transfusion, is a more important risk factor for the production of anti-HLA antibodies.…”
Section: Discussionmentioning
confidence: 69%
“…In addition, anti‐HLA antibody specificities were determined by LABScreen Single Antigen beads assay (One Lambda). Each step was performed in accordance with the manufacturer's instructions, as previously reported 22–24 . The MFI of anti‐HLA antibodies was calculated from the results after normalization to the negative control.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…42,43 This disparity in the presence of anti-HLA antibodies between our study and other studies might be a result of the differences in age, gender, type of disease, the number of transfusions, as well as the number of previous pregnancies. [42][43][44] The cross-match by CDC procedure was performed for all our patients and it was negative in 98.3% cases, the only exception was one female patient who had positive CM but also a high level of DSA (MFI 15 000). Because there were no other available donors for this patient, the decision was to proceed with the desensitization protocol prior to HSCT.…”
Section: Ta B L Ementioning
confidence: 92%